Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-27 07:30 |
Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 publish…
|
English | 389.3 KB | ||
| 2024-07-31 17:00 |
Transgene annonce la mise à disposition d’un prospectus dans le cadre de la co…
|
French | 363.9 KB | ||
| 2024-07-30 21:01 |
Transgene renforce son bilan par la conversion en actions d’une partie de l’ava…
|
French | 508.0 KB | ||
| 2024-07-22 08:00 |
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2…
|
English | 358.0 KB | ||
| 2024-07-22 08:00 |
Transgene et BioInvent présentent un poster sur le virus oncolytique BT-001, à …
|
French | 394.8 KB | ||
| 2024-07-10 18:00 |
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 30 juin 2…
|
French | 167.9 KB | ||
| 2024-07-10 18:00 |
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30…
|
English | 194.8 KB | ||
| 2024-06-03 07:30 |
Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Tr…
|
English | 476.0 KB | ||
| 2024-06-03 07:30 |
Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisé…
|
French | 458.8 KB | ||
| 2024-05-15 17:45 |
Assemblée Générale Mixte de Transgene du 15 mai 2024
|
French | 272.7 KB | ||
| 2024-05-15 17:45 |
Transgene’s Combined General Meeting of May 15, 2024
|
English | 276.4 KB | ||
| 2024-05-15 16:00 |
Franchissement de seuil
|
French | 201.5 KB | ||
| 2024-05-14 17:45 |
Transgene fait le point sur ses activités et sa situation financière au premier…
|
French | 278.3 KB | ||
| 2024-05-14 17:45 |
Transgene provides business and financial update for Q1 2024
|
English | 324.8 KB | ||
| 2024-04-24 17:45 |
Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai…
|
French | 244.5 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
